DIAmond Session 203: “Innovation is Clearly Happening”: Next Generation Collaboration: Transforming the Industry

The DIA2016 panel discussion Next Generation Collaboration: Transforming the Industry focused on convergence, collaboration and cooperation in drug development. These activities, performed early and often amongst all stakeholders, can drive greater innovation, reduce time to market and increase efficacy in product development: There are 560 drugs currently in development for rare diseases; HIV, once a death sentence, is now a chronic disease; Hepatitis has a cure; and Melanoma, long considered untreatable, is now managed by a number of new drugs. In 2015, the FDA approved 51 new drugs, all new class agents, the largest number of approvals over the past 66 years. Featured Speakers: Dr. Dalvir Gill, CEO of TransCelerate BioPharma, Inc.; Dr. Christopher Austin, Director, National Center for Advancing Translational Sciences, National Institutes of Health; Dr. C. David Nicholson, Allergan Executive Vice President, Brand R&D; Dr. Jonathan Jarow, Senior Medical Advisor to the Center Director, CDER, FDA; Margaret Anderson, Executive Director, FasterCures, A Center of the Milken Institute; and Drew Schiller, Co-Founder and Chief Technology Officer, Validic.